14,750 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 14,750 shares of the company’s stock, valued at approximately $162,000.

Several other institutional investors and hedge funds have also modified their holdings of ITOS. Exchange Traded Concepts LLC raised its position in iTeos Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 11,379 shares of the company’s stock valued at $125,000 after purchasing an additional 2,885 shares during the last quarter. Vanguard Group Inc. raised its position in iTeos Therapeutics by 2.3% in the third quarter. Vanguard Group Inc. now owns 1,813,759 shares of the company’s stock valued at $19,861,000 after purchasing an additional 40,407 shares during the last quarter. Deutsche Bank AG raised its position in iTeos Therapeutics by 11.6% in the third quarter. Deutsche Bank AG now owns 24,631 shares of the company’s stock valued at $270,000 after purchasing an additional 2,552 shares during the last quarter. Comerica Bank bought a new position in iTeos Therapeutics in the third quarter valued at about $134,000. Finally, Sectoral Asset Management Inc. raised its position in iTeos Therapeutics by 5.8% in the third quarter. Sectoral Asset Management Inc. now owns 155,075 shares of the company’s stock valued at $1,698,000 after purchasing an additional 8,499 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ITOS shares. Wedbush reiterated an “outperform” rating and issued a $18.00 target price (down from $25.00) on shares of iTeos Therapeutics in a research report on Wednesday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 7th.

iTeos Therapeutics Price Performance

Shares of ITOS opened at $11.76 on Tuesday. iTeos Therapeutics, Inc. has a 1 year low of $8.20 and a 1 year high of $18.24. The company has a market capitalization of $421.48 million, a price-to-earnings ratio of -3.73 and a beta of 1.19. The business has a 50-day moving average of $11.37 and a 200-day moving average of $10.59.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.18. As a group, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -4.76 EPS for the current year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.